Please login to the form below

Not currently logged in
Email:
Password:

Otsuka in-licenses leukaemia biologic for USD 200m

Otsuka buys the North American rights to PDL Biopharma's leukaemia drug, IV Busulfex, for USD 200m in cash to boost its global cancer franchise

Privately held Japanese pharmaceutical company Otsuka has agreed to buy North American rights to US biopharmaceutical company PDL Biopharma's leukaemia drug, IV Busulfex, for USD 200m in cash to boost its global cancer franchise.

Otsuka and PDL will complete the transaction by March 2008, according to a joint statement release on 17 December. PDL's partners will keep the rights to sell the medicine outside of North America, according to the statement.

IV Busulfex is already sold in more than 40 countries, but Otsuka wants to develop the drug for wider use in the important US market.

PDL revealed in October 2007 that it would sell itself entirely or its key assets.

The financial advisor to Otsuka in the transaction was Montgomery & Co, while PDL was advised by Merrill Lynch & Co.

19th December 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....
Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...